For instance, the National Institute on Aging and the Alzheimer’s Association defined these biomarkers as the framework of the A/T/N (amyloid/tau/neurodegeneration) system for Alzheimer’s disease diagnosis. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.